| dc.identifier.citation |
Dahl VN, Skouvig Pedersen O, Butova T, Kuzhko M, Raznatovska O, Fedorec A, Vekshyn V, Hlynenko V, Yevsiukova N, Hryshchuk L, Kornaha S, Chursina N, Kondratyuk N, Markovtsiy L, Skryp V, Bogomolov A, Klymenko T, Yankovska D, Ostrovskyy M, Makoida I, Levandovska D, Shpak Y, Didyk V, Siomak O, Butov D. Effectiveness of the Bedaquiline, Pretomanid, and Linezolid Regimen, With or Without Moxifloxacin, for Drug-Resistant Tuberculosis in Ukraine Under Programmatic Conditions. Clin Infect Dis. 2025 Nov 6;81(4):853-856. doi: 10.1093/cid/ciaf214. PMID: 40280886; PMCID: PMC12596402. |
uk_UA |
| dc.description.abstract |
Bedaquiline, pretomanid, and linezolid, with or without moxifloxacin, have revolutionized treatment for drug-resistant tuberculosis. In Ukraine, we observed an 86% success rate (394 of 460) under programmatic conditions when drugs were accessible, exceeding prior estimates (58%) and aligning with trial findings (80%-90%). However, access and implementation remain a concern in conflict-affected settings. |
uk_UA |